Clinical trial
Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)
NCT00348153 · Heidelberg University, Other · Unknown status
Key facts
| NCT number | NCT00348153 |
|---|---|
| Title | Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) |
| Official title | Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients With Different Forms of Refractory Uveitis Acronym: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) |
| Lead sponsor | Heidelberg University, Other |
| Collaborators | Abbott Industry |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Uveitis |
| Intervention type | Drug |
| Interventions | Adalimumab |
| Enrollment | 40 |
| Start date | Aug 1, 2006 |
| Primary completion | Sep 1, 2012 |
| Completion | Mar 1, 2013 |
| First posted | Jul 4, 2006 |
| Last update posted | Dec 3, 2012 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: